glp 1 and bone loss Effects of Glucagon-Like Peptide-1 receptor agonists on health in people living with obesity | Osteoporosis International GLP-1 Medications + Bone Health

Multiple randomized controlled trials and meta-analyses in patients with type 2 diabetes and obesity demonstrate that GLP-1RA therapy either preserves or modestly increases bone mineral density (BMD) at key skeletal sites lumbar spine and hip, GLP-1RAs also favorably modulate bone turnover markers, increasing bone formation markers (P1NP, osteocalcin, bone-specific alkaline phosphatase) and reducing bone resorption markers (-CTX), suggesting a net positive or neutral effect on bone remodeling

LegitScripts findings show both a rapid rise in demand for Healthcare Certification by businesses offering compounded GLP-1 drugs, as well as a sharp increase in problematic GLP-1 products being peddled online that are violating laws across jurisdictions worldwide and potentially endangering unsuspecting consumers.

Despite having fasted for 18 hr, and differing from the findings of prior procedures, endoscopy revealed substantial gastric content, which was suctioned before endotracheal intubation

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy

Archives of physiology and biochemistry, 130(6), 678685